The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.
A relatively low-tech stock trade is making Tesla Inc.’s dizzying rally look like an under-performance.
It’s not an easy environment for health-care investors, with the sector front and center of political debates, but a bigger concern might be stemming from a key regulator: the U.S. Food and Drug Administration.
A New York state lawsuit is renewing longstanding questions about where some members of the billionaire Sackler family have invested the wealth they amassed from Purdue Pharma LP, the drugmaker accused of helping ignite the U.S. opioid epidemic.
Makers of medical device implants and diagnostic products proved health care was no monolith after broadly outperforming the U.S. market and their health care brethren in 2018. But 2019 is shaping up quite differently through the first day of trading amid a spotlight from a variety of investment banks.
Increasing wariness in Washington over China’s investments in U.S. biotechnology companies may cool a hot source of capital for medical startups.
As equity investors caught up in the cannabis craze push pot stocks to record highs, options traders are paying the most ever to hedge against a comedown.
As Biogen Inc. prepares to kick off earnings season Tuesday for a beaten-down large-cap biotechnology sector, investors won’t be too focused on the financial results.
